Tsingke Biotech is a global leader in synthetic biology, leveraging AI-driven technologies to advance gene synthesis and life science innovation. We provide high-performance gene synthesis platforms and end-to-end solutions, from raw material production to GMP-grade nucleic acids, supporting both research and industrial applications.
Our integrated platform enables high-throughput oligonucleotide synthesis, antibody discovery and development, and strain engineering and screening. With over 20 years of experience, we serve more than 300,000 customers worldwide, including academic institutions, biotechnology companies, diagnostic developers, and pharmaceutical manufacturers.
By integrating research, development, manufacturing, and commercialization, we help translate scientific discoveries into scalable applications across research, diagnostics, and therapeutics.
Biotech for a Better World—Advancing scientific discovery through precision nucleic acid manufacturing.
Building the Great Tsingke Gene Factory: the world's most integrated and efficient DNA/RNA synthesis platform.
Founded; commenced operations in nucleic acid synthesis
Founded; commenced operations in nucleic acid synthesis
Expanded into the production of chemical raw materials
Expanded into the production of chemical raw materials
Launched professional-grade gene sequencing services
Launched professional-grade gene sequencing services
Launched oligonucleotide synthesis and advanced modification services
Launched oligonucleotide synthesis and advanced modification services
Developed proprietary automated synthesizers and equipment
Developed proprietary automated synthesizers and equipment
Expanded into molecular reagent production
Expanded into molecular reagent production
Incorporated as Tsingke Biotechnology Co., Ltd.; specialized in high-throughput gene synthesis
Incorporated as Tsingke Biotechnology Co., Ltd.; specialized in high-throughput gene synthesis
Closed $21M Series A funding; expanded into the protein & antibody sector
Closed $21M Series A funding; expanded into the protein & antibody sector
Secured USD 56 million in Series B funding and launched R&D in gene regulation and small nucleic acid therapeutics
Secured USD 56 million in Series B funding and launched R&D in gene regulation and small nucleic acid therapeutics
Converted to a joint-stock company: Beijing Tsingke Biotech Co., Ltd.
Converted to a joint-stock company: Beijing Tsingke Biotech Co., Ltd.
Listed on the NEEQ
Listed on the NEEQ
Tsingke's operations are strategically distributed
across China to support the Gene Factory concept
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
